Affimed NV (NASDAQ:AFMD) was founded in 2000. Its predecessor was Affimed Therapeutics BV. It was changed to its current name in October 2014. It is headquartered in Heidelberg, Germany. It has 80 full-time employees. It is a clinical-stage biopharmaceutical company focusing on Discovery and development of cancer immunotherapy in the United States, Europe and Germany.
Affimed NV (AFMD):
Affimed is a clinical-stage biopharmaceutical company that focuses on cancer immunotherapy research. The candidate products are mainly in the field of tumor immunity. Affimed’s TandAbs global patent platform technology can enable NK cells and T cells to lyse tumor cells. The products are Contains AFM13 (developed in collaboration with The Leukemia & Lymphoma Society).
Affimed’s main product candidate, AFM13, a natural killer cell (NK cell) TandAb, is in phase IIa clinical research for the treatment of recurrent CD30-positive lymphoma; and is in the PD-1 antibody Keytruda (pembrolizumab) for the treatment of relapsed Phase Ib clinical study of Chikin’s lymphoma.
Affimed’s products include AFM24, NK cell bispecific antibody targeting EGFR-wild type represents a validated antigen expressed by various solid tumors; AFM26, combined with B cell maturation antigen (BCMA), used to treat multiple bone marrow Tumor; and Trispecific Abs (trispecific antibodies) for the treatment of multiple myeloma.
Affimed products also include AFM11, a T-cell TandAb, currently in phase I clinical trials in patients with recurrent CD19 + B-cell malignancies, including non-Hodgkin’s lymphoma and acute lymphoblastic leukemia (AML); AMV564, CD33 / CD3-specific T cell TandAb is in phase I clinical research for refractory AML.
Affimed NV has a license agreement with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum and Xoma Ireland Limited; a research grant agreement with The Leukemia & Lymphoma Society; and a cooperation agreement with Merck Sharp & Dohme BV.
In addition, Affimed has also conducted clinical development and commercialization cooperation with the University of Texas MD Anderson Cancer Center to evaluate the combination of AFM13 and MD Anderson’s NK cell products.
On August 28, 2018, Affimed announced that it had reached a US$5 billion cooperation with Genentech, a subsidiary of Roche, and its stock price soared by nearly 250%.